SCHEMBL273976

SCHEMBL273976

O=C(Nc1ccc(Br)cc1C(=O)N/N=C/c1ccc(Cl)c(C(F)(F)F)c1)c1cccc(CSc2nc[nH]n2)c1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC34A2 O95436 10/20 0.44
SLC34A1 Q06495 1/20 0.44
SLC34A3 Q8N130 1/20 0.44
SLC20A1 Q8WUM9 1/20 0.44
ADCYAP1R1 P41586 5/20 0.39
LMNA P02545 2/20 0.39
POLB P06746 2/20 0.39
ALDH1A1 P00352 2/20 0.38
HPGD P15428 2/20 0.38
MEN1 O00255 1/20 0.38
THRB P10828 1/20 0.38
KMT2A Q03164 1/20 0.38
MAPT P10636 2/20 0.37
KDM4E B2RXH2 1/20 0.37
HTT P42858 1/20 0.37
NPC1 O15118 1/20 0.36
PKM P14618 1/20 0.36
RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL266177 1.00 SLC34A2 (0.44) SLC34A2SLC34A1SLC34A3SLC20A1ADCYAP1R1
SCHEMBL266942 0.93 SLC34A2 (0.52) SLC34A2SLC34A1SLC34A3SLC20A1ADCYAP1R1
SCHEMBL273883 0.93 SLC34A2 (0.52) SLC34A2SLC34A1SLC34A3SLC20A1ADCYAP1R1
SCHEMBL268528 0.88 SLC34A2 (0.47) SLC34A2SLC34A1SLC34A3SLC20A1LMNA
SCHEMBL273406 0.88 SLC34A2 (0.47) SLC34A2SLC34A1SLC34A3SLC20A1LMNA
SCHEMBL273575 0.87 SLC34A2 (0.55) SLC34A2SLC34A1SLC34A3SLC20A1LMNA
SCHEMBL266842 0.87 SLC34A2 (0.55) SLC34A2SLC34A1SLC34A3SLC20A1LMNA
SCHEMBL273541 0.86 SLC34A2 (0.46) SLC34A2SLC34A1SLC34A3SLC20A1ADCYAP1R1
SCHEMBL267708 0.86 SLC34A2 (0.46) SLC34A2SLC34A1SLC34A3SLC20A1ADCYAP1R1
SCHEMBL266894 0.86 SLC34A2 (0.43) SLC34A2SLC34A1SLC34A3SLC20A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 SLC34A2 2/4885SLC34A1 1/4885SLC34A3 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.